title: Infection control programs at children's hospitals: a description of structures and processes.
abstract: BACKGROUND
  Infection control (IC) structures and processes determine the effectiveness of surveillance efforts to prevent infections in health care settings.
  
  
  METHODS
  A survey was sent to 56 children's hospitals collaborating in the Pediatric Prevention Network (PPN).
  
  
  RESULTS
  Completed surveys were returned from 48 hospitals. Responsibility for the IC program resided with the medical director (21%); vice president for patient care (18%); quality improvement director (17%); other senior hospital administrator (15%); or other hospital personnel (18%). Forty-two hospitals had an IC committee; 32 had antimicrobial restriction/control policies; and 21 had an antimicrobial restriction/control task force or committee. Components of antimicrobial restriction programs included infectious disease specialist approval, restricted formularies, selective susceptibility test reporting, and staff education programs. Many methods were used to detect infections, including microbiology laboratory reports (100%); record reviews (98%); informal reports from providers (90%); and readmission reviews (77%).
  
  
  CONCLUSIONS
  Children's hospitals vary widely in how they design and implement their IC functions. These variations influence adverse event detection and nosocomial infection rate calculations. If medical errors, including nosocomial infections, are to be detected and hospital rates compared, standardized methods to collect, analyze, and report data are needed. The PPN has initiated activities to standardize surveillance and IC practices in participating hospitals.
authors.affiliation: National Association of Children's Hospitals and Related Institutions, Alexandria, VA 22314, USA.
authors.forename: S
authors.initials: S
authors.lastname: Girouard
authors.forename: G
authors.initials: G
authors.lastname: Levine
authors.forename: K
authors.initials: K
authors.lastname: Goodrich
authors.forename: S
authors.initials: S
authors.lastname: Jones
authors.forename: H
authors.initials: H
authors.lastname: Keyserling
authors.forename: M
authors.initials: M
authors.lastname: Rathore
authors.forename: C
authors.initials: C
authors.lastname: Rubens
authors.forename: E
authors.initials: E
authors.lastname: Williams
authors.forename: W
authors.initials: W
authors.lastname: Jarvis
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D003428:Cross Infection / Q000453:epidemiology / Q000517:prevention & control; D006776:Hospitals, Pediatric / Q000458:organization & administration*; D006801:Humans; D017053:Infection Control / Q000458:organization & administration*; D015278:Intensive Care Units, Pediatric; D007755:Laboratories, Hospital / Q000458:organization & administration; D016134:Organizational Policy; D011159:Population Surveillance / Q000379:methods; D011367:Professional Staff Committees; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents